| 4.17 -0.01 (-0.24%) | 04-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.25 | 1-year : | 6.13 |
| Resists | First : | 4.5 | Second : | 5.25 |
| Pivot price | 4.08  |
|||
| Supports | First : | 4.04 | Second : | 3.76 |
| MAs | MA(5) : | 4.13 |
MA(20) : | 4.07  |
| MA(100) : | 4.7 |
MA(250) : | 4.42 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 73.7 |
D(3) : | 69.4 |
| RSI | RSI(14): 53.2 |
|||
| 52-week | High : | 7.55 | Low : | 2.11 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AQST ] has closed below upper band by 26.5%. Bollinger Bands are 74.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.21 - 4.24 | 4.24 - 4.26 |
| Low: | 4.07 - 4.09 | 4.09 - 4.11 |
| Close: | 4.13 - 4.17 | 4.17 - 4.21 |
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Thu, 09 Apr 2026
AQUESTIVE THERAPEUTICS, INC. (AQST) DEADLINE ALERT - GlobeNewswire
Thu, 09 Apr 2026
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Tue, 07 Apr 2026
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit - ChartMill
Mon, 06 Apr 2026
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With ... - Caledonian Record
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 122 (M) |
| Shares Float | 112 (M) |
| Held by Insiders | 3.4 (%) |
| Held by Institutions | 62.1 (%) |
| Shares Short | 17,680 (K) |
| Shares Short P.Month | 20,040 (K) |
| EPS | -0.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.29 |
| Profit Margin | -188.1 % |
| Operating Margin | -221.6 % |
| Return on Assets (ttm) | -34 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 9.6 % |
| Gross Profit (p.s.) | 0.21 |
| Sales Per Share | 0.36 |
| EBITDA (p.s.) | -0.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -5.35 |
| PEG Ratio | 0 |
| Price to Book value | -14.9 |
| Price to Sales | 11.42 |
| Price to Cash Flow | -9.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|